This article is currently undergoing investigation.
Research Paper Volume 13, Issue 11 pp 15285—15306

Mesenchymal stem cells-derived extracellular vesicles ameliorate Alzheimer’s disease in rat models via the microRNA-29c-3p/BACE1 axis and the Wnt/β-catenin pathway


Figure 9. BM-MSC-EVs-carried miR-29c-3p inhibits BACE1 in AD. BM-MSC-EVs could be internalized by neuronal cells and then released their carried miR-29c-3p to upregulate miR-29c-3p expression in neurons. The upregulation of miR-29c-3p inhibited BACE1 and then activated the Wnt/β-catenin pathway to reduce levels of Aβ1-42 and inflammatory cytokine (IL-1β, IL-6 and TNF-α), thereby playing a therapeutic role in the treatment of AD.